These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31269758)

  • 1. Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice.
    Qian M; Lyu Q; Liu Y; Hu H; Wang S; Pan C; Duan X; Gao Y; Qi LW; Liu W; Wang L
    Mar Drugs; 2019 Jul; 17(7):. PubMed ID: 31269758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitosan Oligosaccharide Attenuates Nonalcoholic Fatty Liver Disease Induced by High Fat Diet through Reducing Lipid Accumulation, Inflammation and Oxidative Stress in C57BL/6 Mice.
    Tao W; Sun W; Liu L; Wang G; Xiao Z; Pei X; Wang M
    Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31744059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis
    Liu MT; Huang YJ; Zhang TY; Tan LB; Lu XF; Qin J
    World J Gastroenterol; 2019 Jul; 25(27):3590-3606. PubMed ID: 31367159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats.
    Lensu S; Pariyani R; Mäkinen E; Yang B; Saleem W; Munukka E; Lehti M; Driuchina A; Lindén J; Tiirola M; Lahti L; Pekkala S
    Nutrients; 2020 Oct; 12(11):. PubMed ID: 33105554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of Ilexhainanoside D and ilexsaponin A
    Zhao W; Xiao M; Yang J; Zhang L; Ba Y; Xu R; Liu Z; Zou H; Yu P; Wu X; Chen X
    Phytomedicine; 2019 Oct; 63():153039. PubMed ID: 31387054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE
    Ma Y; Chen K; Lv L; Wu S; Guo Z
    Biomed Pharmacother; 2019 May; 113():108753. PubMed ID: 30856537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
    Lee JE; Lee SM; Jung J
    Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzbromarone aggravates hepatic steatosis in obese individuals.
    Sun P; Zhu JJ; Wang T; Huang Q; Zhou YR; Yu BW; Jiang HL; Wang HY
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2067-2077. PubMed ID: 29526820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis.
    Qian M; Hu H; Yao Y; Zhao D; Wang S; Pan C; Duan X; Gao Y; Liu J; Zhang Y; Yang S; Qi LW; Wang L
    Liver Int; 2020 Mar; 40(3):622-637. PubMed ID: 31782595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
    Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
    Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilostazol Attenuates Hepatic Steatosis and Intestinal Disorders in Nonalcoholic Fatty Liver Disease.
    Min T; Qiu S; Bai Y; Cao H; Guo J; Su Z
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis.
    Zhang L; Wang P; Shi M; Fang Z; Ji J; Liao X; Hu X; Chen F
    J Nutr Biochem; 2020 Jun; 80():108365. PubMed ID: 32217466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.
    Moreira GV; Azevedo FF; Ribeiro LM; Santos A; Guadagnini D; Gama P; Liberti EA; Saad M; Carvalho C
    J Nutr Biochem; 2018 Dec; 62():143-154. PubMed ID: 30292107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
    Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
    World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
    J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
    Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
    Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.